Products
Lirentelimab Biosimilar Monoclonal Antibody (Siglec-8) for Research
Pre-Made Lirentelimab biosimilar, Whole mAb, Anti-SIGLEC8/Siglec-8 Antibody: Anti-SAF2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lirentelimab (sold under the brand name AK002) is a humanized nonfucosylated monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). In a randomized clinical trial, lirentelimab was found to improve eosinophil counts and symptoms in individuals with eosinophilic gastritis and duodenitis. Adverse reactions include infusion reactions, which are mild to moderate and typically occur following the first infusion.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-315-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Lirentelimab biosimilar, Whole mAb, Anti-SIGLEC8/Siglec-8 Antibody: Anti-SAF2 therapeutic antibody |
| INN Name | Lirentelimab |
| Target | SIGLEC8 |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | na |
| Companies | Allakos |
| Conditions Approved | na |
| Conditions Active | Eosinophilic gastroenteritis;Eosinophilic oesophagitis;Urticari;Atopic dermatitis;Chronic obstructive pulmonary disease |
| Conditions Discontinued | Conjunctiviti;Fibrosis;Kertoconjunctivitis;Systemic mastocytosis |
| Development Tech | na |
About target - SIGLEC8
1. Protein Sialic acid-binding Ig-like lectin 8
2. Gene SIGLEC8
3. Organism Homo sapiens (Human)
Function
Putative adhesion molecule that mediates sialic-acid dependent binding to red blood cells (PubMed:10856141, PubMed:10625619).
Preferentially binds to alpha-2,3-linked sialic acid. Also binds to alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface (PubMed:10625619).
Recognizes simultaneously epitopes having a terminal N-acetylneuraminic acid (sialic acid) and an underlying 6-O-sulfated galactose. Preferentially binds to Gal-6-sulfated sialyl-Lewis X glycan epitopes (PubMed:27357658).
